Results 201 to 210 of about 552,750 (375)

Costs and Benefits of Prenatal Screening For Cystic Fibrosis [PDF]

open access: yes
Newly-developed genetic tests based on restriction fragment length polymorphisms (RFLPs) promise to facilitate the early detection of genetic diseases. Several such tests are now available for the prenatal detection of cystic fibrosis (CF), a common and ...
Alan M. Garber, Joseph P. Fenerty
core  

A Phase I, First‐In‐Human Study of CBA‐1205, an Anti‐DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

open access: yesCancer Science, Volume 116, Issue 4, Page 1012-1022, April 2025.
We conducted a Phase I trial of CBA‐1205, a novel monoclonal antibody targeting DLK1, in advanced solid tumors, demonstrating safety and tolerability with no dose‐limiting toxicities. Preliminary efficacy was observed, with six patients achieving stable disease for over 6 months, and sDLK1 was identified as a potential biomarker associated with ...
Yuki Katsuya   +12 more
wiley   +1 more source

A Rare Diagnosis of Caroli Syndrome in a Young Patient [PDF]

open access: yesClin Case Rep
ABSTRACT Caroli syndrome is a rare but serious congenital disorder associated with portal hypertension and polycystic kidney disease. Early diagnosis via imaging, particularly MRCP, is crucial to prevent life‐threatening complications such as cholangitis and biliary cirrhosis.
Karimzadeh‐Soureshjani E   +4 more
europepmc   +2 more sources

Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Context Androgen excess is common in women and refers to clinical or biochemical evidence of elevated androgenic steroids such as testosterone. It is associated with underlying polycystic ovary syndrome in the majority of cases. However severe androgen excess is less common and may indicate the presence of underlying adrenal or ovarian ...
Yasir S. Elhassan   +14 more
wiley   +1 more source

Safety and effectiveness of fingolimod in Japanese patients with multiple sclerosis: Results of a post‐marketing surveillance study

open access: yesClinical and Experimental Neuroimmunology, Volume 16, Issue 2, Page 118-131, May 2025.
Abstract Objective Fingolimod is the first oral sphingosine‐1‐phosphate receptor modulator approved in Japan for multiple sclerosis (MS). A large Japanese observational study of fingolimod in patients with MS was carried out to support its safety and effectiveness in a real‐world setting.
Noriko Sato   +7 more
wiley   +1 more source

Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin.

open access: yesKidney International, 2014
A. Ekici   +22 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy